May 2, 2013 / 10:27 AM / 5 years ago

Valeant posts bigger loss as costs rise

(Reuters) - Valeant Pharmaceuticals International Inc (VRX.TO) (VRX.N), Canada’s biggest publicly traded drugmaker, reported a bigger first-quarter loss as expenses rose due to its $2.6 billion acquisition of Medicis Pharmaceuticals Corp.

    The company’s net loss widened to $27.5 million, or 9 cents per share, from $12.9 million, or 4 cents per share, a year earlier.

    Cash earnings, or profit adjusted for one-time items, amounted to $1.30 per share.

    Reporting by Bhaswati Mukhopadhyay; Editing by Saumyadeb Chakrabarty

    0 : 0
    • narrow-browser-and-phone
    • medium-browser-and-portrait-tablet
    • landscape-tablet
    • medium-wide-browser
    • wide-browser-and-larger
    • medium-browser-and-landscape-tablet
    • medium-wide-browser-and-larger
    • above-phone
    • portrait-tablet-and-above
    • above-portrait-tablet
    • landscape-tablet-and-above
    • landscape-tablet-and-medium-wide-browser
    • portrait-tablet-and-below
    • landscape-tablet-and-below